2024-11-01 I-Mab Biopharma HaiPress

ROCKVILLE,Md.,Oct. 31,2024 -- I-Mab (NASDAQ: IMAB) (the "Company"),a US-based,global biotech company,exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer,today announced that it plans to release financial results for the third quarter ended September 30,2024,on Thursday,November 14,pre-market Eastern Time.
The Company will not host a conference call to discuss its third quarter 2024 financial results. The Company intends to host an investor update call in conjunction with its 2024 full-year financial results to discuss its clinical pipeline,corporate strategy,and objectives. Information about financial results,conference calls,webcasts,and other information is posted on the Company's website.
AboutI-Mab
I-Mab (NASDAQ: IMAB) is a US-based,exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer.
I-Mab has established operations in Rockville,Maryland,and Short Hills,New Jersey.For more information,please visithttps://www.i-mabbiopharma.comand followus onLinkedInandX.
I-Mab Investor & Media Contacts
Tyler Ehler
Senior Director,Investor Relations
IR@imabbio.com
China's Robotaxi Scales Up: Caocao Mobility Forges World's Only Full-Element Closed-Loop Ecosystem
AlphAi Expands Its Trading Ecosystem Through Polymarket-Compatible Prediction Markets
A New Era of Global Intelligent Networks Begins:LCT DePIN AI Network Infrastructure Official Presale Launches on July 15
China Eastern Airlines Extends Complimentary Wi-Fi to Entire Wide-body Fleet, Marking Milestone in In-flight Connectivity
SeerQ, in partnership with Linfeng Capital, is hosting a Confucian-Taoist conference. Sister Muyun's numerological modeling and Guo Sizhi's prediction of a major bull market in 2029
Fungsui Culture Lecture Explores Zhuangzi's Realm of Freedom – Enthusiastic Reception Collaborating with SeerQ to Promote Taoist Wisdom of Carefree Living
©copyright 2009-2020 Diet Tips Daily